Vivoryon Therapeutics VVY

AMS: VVY | ISIN: NL00150002Q7   11/09/2026
1,120 EUR (-0,88%)
(-0,88%)   11/09/2026

18 augustus 2026 · Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 · Persbericht

6 augustus 2026 · Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update · Persbericht

22 juli 2026 · Vivoryon Therapeutics N.V. to Report H1 2026 Financial Results and Business Updates on August 6, 2026; Annual General Meeting Planned for End of September 2026 · Persbericht

11 juni 2026 · Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update · Persbericht

8 juni 2026 · Vivoryon Therapeutics N.V. to Report Q1 2026 Financial Results on June 11, 2026 · Persbericht

23 april 2026 · Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update · Persbericht

15 april 2026 · Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates on April 23, 2026 · Persbericht

9 april 2026 · Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference · Persbericht

28 maart 2026 · Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology · Persbericht

7 januari 2026 · Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences · Persbericht

4 december 2025 · Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates · Persbericht

25 november 2025 · Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational Progress on December 4, 2025 · Persbericht

6 november 2025 · Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025 · Persbericht

3 november 2025 · Vivoryon Therapeutics N.V. to Present at Upcoming Conferences · Persbericht

6 oktober 2025 · Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million · Persbericht

4 september 2025 · Vivoryon Therapeutics N.V. Reports H1 2025 Financial Results and Business Updates · Persbericht

27 augustus 2025 · Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress on September 4, 2025 · Persbericht

27 juni 2025 · Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences · Persbericht

24 juni 2025 · Vivoryon Therapeutics N.V. Reports Outcome of 2025 Annual General Meeting · Persbericht

17 juni 2025 · Mee met de markt: “Beleggers in egelstelling” · Bolero.be

Terwijl het militaire conflict tussen Israël en Iran een laag van onzekerheid toevoegt aan de sowieso al precaire wereldeconomie én de geopolitieke ontwikkelingen, blijven de financiële markten al bij al op hun gemak. De...

Mijn selecties